NEW YORK (GenomeWeb News) – Cellectis and Genoway said that they have reached an agreement on how to handle orders of products covered by a licensing agreement between the firms that was terminated in late 2008.
In December 2008, Cellectis terminated a non-exclusive license that granted Genoway access to patents covering certain uses of homologous recombination. The initial license had been signed in 2001.
The firms said yesterday that under their agreement Genoway would be allowed to deliver the orders placed after termination of the deal and before Nov. 12, 2009. Paris-based Cellectis said in a statement that a visa of Cellectis will be attached to the delivery of such orders.